Reuters logo
Lilly's lung cancer drug fails late-stage study
October 10, 2017 / 10:59 AM / 7 days ago

Lilly's lung cancer drug fails late-stage study

Oct 10 (Reuters) - Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study.

Lilly’s abemaciclib, however, showed some evidence of improvement in the secondary goals, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below